Physician profile
Michael Ryan
NPI 1962488668
$335,169.85
in general payments reported to CMS, 2019-2025
44 companies · $86K in 2025
The $86K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $8,930 · 2021: $49K · 2022: $30K · 2023: $48K · 2024: $67K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $26K · Consulting Fee: $13K · Travel and Lodging: $13K · Food and Beverage: $8,686 · Honoraria: $7,361 · Education: $29.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $131,864.38 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $25,870.00 |
| Consulting Fee | $13,457.50 |
| Travel and Lodging | $12,924.39 |
| Food and Beverage | $8,686.04 |
| Honoraria | $7,361.25 |
| Education | $29.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $102,036.07 | 2019-2025 | Epclusa, Livdelzi |
| Intercept Pharmaceuticals, INC. | $98,269.20 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $42,652.50 | 2024-2025 | Iqirvo, Bylvay |
| Abbvie INC. | $34,002.32 | 2019-2025 | Skyrizi, Mavyret, Rinvoq |
| Madrigal Pharmaceuticals | $31,290.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $23,487.33 | 2023-2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $627.87 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $375.36 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.29 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $202.08 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $189.87 | 2022-2025 | Dupixent |
| Conmed Corporation | $172.71 | 2020 | |
| Pfizer INC. | $125.67 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $124.20 | 2019 | |
| Qol Medical, LLC | $116.11 | 2019-2025 | Sucraid, Sucraid |
Show all 42 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.